Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC506 in Advanced Gastric/GEJ Adenocarcinoma
NCT06353152Phase 1Recruiting
- Sponsor
- Peking University
- Start
- Nov 2023
- Primary completion
- Nov 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC506 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Peking University. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 48 weeks. Started Nov 2023; status: recruiting.
02
Drugs
GC506
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06353152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06353152.